Demographics and clinical characteristics at baseline of patients with csEVH in the 301 study
| Variable . | Eculizumab (n = 30) . | Ravulizumab (n = 29) . |
|---|---|---|
| Age at PNH diagnosis, n, mean ± SD (range), y | 30 40.3 ± 17.0 (15-82) | 28 40.5 ± 16.6 (17-73) |
| PNH clone size, mean ± SD (range) | ||
| RBC type II | 11.1 ± 13.7 (0.3-59.1) | 11.1 ± 14.3 (0.3-50.2) |
| RBC type III | 22.7 ± 14.2 (2.4-63.3) | 21.1 ± 15.1 (2.9-75.9) |
| Total RBC | 33.8 ± 22.3 (3.3-98.0) | 32.3 ± 20.1 (9.2-78.0) |
| Granulocytes | 93.6 ± 5.3 (80.2-99.6) | 92.2 ± 12.2 (43.9-99.9) |
| Monocytes | 94.7 ± 5.0 (83.3-99.9) | 92.8 ± 14.0 (28.6-99.9) |
| Variable . | Eculizumab (n = 30) . | Ravulizumab (n = 29) . |
|---|---|---|
| Age at PNH diagnosis, n, mean ± SD (range), y | 30 40.3 ± 17.0 (15-82) | 28 40.5 ± 16.6 (17-73) |
| PNH clone size, mean ± SD (range) | ||
| RBC type II | 11.1 ± 13.7 (0.3-59.1) | 11.1 ± 14.3 (0.3-50.2) |
| RBC type III | 22.7 ± 14.2 (2.4-63.3) | 21.1 ± 15.1 (2.9-75.9) |
| Total RBC | 33.8 ± 22.3 (3.3-98.0) | 32.3 ± 20.1 (9.2-78.0) |
| Granulocytes | 93.6 ± 5.3 (80.2-99.6) | 92.2 ± 12.2 (43.9-99.9) |
| Monocytes | 94.7 ± 5.0 (83.3-99.9) | 92.8 ± 14.0 (28.6-99.9) |
SD, standard deviation.